Global R&D organisations have increased their spend on data integration initiatives to drive product innovation (drugs, companion diagnostics, personal care) or accurately predict phenotypic traits (disease susceptibility, patient stratification..
In my day to day work at Eagle, all of the projects I work on need tools installed. Bioinformatics tools infrequently come in one simple bundle and sometimes the dependencies can be vast and platform dependant. Here at Eagle we embrace the..
Eagle has a proven history of discovering actionable biomarkers in complex molecular datasets. Our success is based on a flexible, disciplined and collaborative approach that puts the researcher’s scientific priorities first. This is..
CAMBRIDGE, April 5, 2016 – Eagle Genomics announces the results of a novel insight on the International Cancer Genome Consortium (https://icgc.org/) data, with over 17,000 patient donors, resulting in a ranking of the most valuable constituent..
Molecular biomarkers are measurable properties that indicate biological state. These are fundamental to the development of today’s precision therapeutics and diagnostics. The current pace of development is phenomenal, but can we go still faster by..
Anthony Finbow has been working since September 2015 in advising Abel Ureta-Vidal (CEO) and the Board of Eagle Genomics in developing the business, in shaping the company’s product vision and in preparing the business for growth. Anthony replaces..
Can I reuse my data ?
As data scientists are fond of telling us, data reuse reduces time to discovery, promotes cost efficiency and ultimately leads to discoveries that would not otherwise have been made. Can organisations currently reuse their..